Industry Sounds Somewhat Muted Drug Pricing Alarm
Pharma CEOs expect the US pricing situation will remain stable in the near-term but accept drug prices will continue to face pressure and agree that the future remains uncertain. Subsiding rhetoric after elections may bring some relief.
You may also be interested in...
From Pharma Insider To Payer: Witty To Lead United's Optum
Former GSK CEO Witty stood out among big pharma chief execs for his pessimistic outlook on US drug pricing, which shaped his diversification strategy at GSK. His experience as a pharma insider makes him an interesting choice to lead United's PBM and health services arm.
Calif. Prop 61 Raises Industry Concerns Over Ripple Effect
Industry executives are speaking out against the measure that would require California state agencies to pay no more than the US Department of Veterans Affairs pay for drugs.
Pfizer’s Read Criticizes Rebates Amid Changing Market Dynamics
Pfizer CEO Ian Read suggested it might be time for a new solution that would allow the pharma industry to moderate pricing based on volume without relying on rebates, criticizing a practice he said has become “less helpful” in getting cost effective solutions to patients.